
Cilag Gets Global Rights to Argenx's Cusatuzumab; Terminates Deal
Executive Summary
Argenx SE licensed Janssen’s Cilag GMBH International exclusive global rights to its cusatuzumab (ARGX110) in blood cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com